# DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES

> **NIH NIH N01** · INIMMUNE CORPORATION · 2024 · $2,515,245

## Abstract

Inimmune is developing a second generation synthetic AS01-like adjuvant system (termed SAS), by partnering our novel fully synthetic TLR4 agonist INI-2002, with a semi-synthetic saponin for use in vaccines. Pre-clinically, SAS has demonstrated excellent antibody and T-cell immune responses when paired with a split flu antigen. This versatile vaccine adjuvant is expected to provide a significant enhancement to the immune response to both viral and bacterial vaccines while exhibiting a favorable safety profile. Under this contract, Inimmune, in collaboration with its subcontracting partners, will optimize, scale-up, and produce cGMP SAS in an effort to advance it to an IND submission.

## Key facts

- **NIH application ID:** 11127341
- **Project number:** 75N93023C00042-P00001-9999-1
- **Recipient organization:** INIMMUNE CORPORATION
- **Principal Investigator:** DAVID BURKHART
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $2,515,245
- **Award type:** —
- **Project period:** 2023-09-30 → 2028-09-29

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11127341

## Citation

> US National Institutes of Health, RePORTER application 11127341, DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES (75N93023C00042-P00001-9999-1). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/11127341. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*